Neumora Therapeutics

Biotech & Life Sciences · Waltham, United States · Founded 2020 · IPO 2023

Pioneering a new era of precision medicines for brain diseases MoreLess

Neumora Therapeutics is pioneering the development of precision medicines for brain diseases, addressing the unmet needs in neuropsychiatric and neurodegenerative disorders. The company operates in the biopharmaceutical sector, focusing on Central Nervous System (CNS) diseases. Neumora's business model revolves around leveraging its proprietary Precision Toolbox, which integrates translational, clinical, and computational tools to develop targeted treatments. This approach aims to revolutionize the treatment landscape by focusing on novel mechanisms of action, rather than traditional drug classes. Neumora serves patients suffering from brain diseases, a market that affects over 1.5 billion people globally. The company generates revenue through the development and commercialization of its innovative drug pipeline, which is designed to offer more effective and targeted treatment options.

Keywords: precision medicine, CNS diseases, neuropsychiatric, neurodegenerative, pharmacology, translational tools, clinical tools, computational tools, drug development, brain diseases.

Valuation $100–500M

Headcount 100–500

Total funding $500M–1B

Power Law Unicorn$1–10B valuation tier

Talent graph

Neumora Therapeutics's talent

Book a demo to see the people

Employees mapped 106 incl. 3 AI specialists

Founders /100 quality score

Key operators 16 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

20 investors on Neumora Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 16 investors entered at this stage

Amgen

ARCH Venture Partners

Altitude Life Science Ventures

Logos Capital

re.Mind Capital

Polaris Partners

Catalio Capital Management

Mubadala Capital

Surveyor Capital

Invus

F-Prime

Alexandria Venture Investments

Waycross Ventures

Exor

Abu Dhabi Growth Fund

Newpath Partners

Series B+ 4 investors entered at this stage

Exor

Newpath Partners

Abu Dhabi Growth Fund

Scripps Translational Science Institute

Global footprint

Where Neumora Therapeutics has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States98.8%

🇧🇷 Brazil1.3%

2 countries shown

Web traffic by country

9K monthly visits
across markets

🇺🇸 United States76.7%

🇨🇦 Canada14.4%

🇮🇳 India7.8%

🇫🇷 France1.1%

Top 4 markets shown

Patent intelligence

$38M patent portfolio · 30 active families

Estimated portfolio value

$38M

18.6% of market cap · 20.8× smaller than top peer BioNTech ($788M)

30 active patent families

Where Neumora Therapeutics innovates Computer programData miningMedicinal chemistryMedicineOpiate receptors

Where Neumora Therapeutics concentrates vs peers

Each axis is a top-10 topic across Neumora Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Neumora Therapeutics

An AI-synthesized read of the highest-engagement posts about Neumora Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neumora Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles